Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-endEnded third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026SAN DIEGO, Nov. 7, 2024 / ...